Shilpa Medicare Limited
Shilpa Medicare Incorporated in 1987 manufactures niche APIs, intermediates, and formulations and also undertakes contract research and manufacturing service for some of its customers. The company’s formulation products consist of 16 injectable dosage forms, 19 oral solid dosage forms under SML and 13 formulations under SML’s wholly owned subsidiary Shilpa Therapeutics.
What Shilpa files
- Important41
- Updates40
- Others36
- Investor Meet26
- Board Meeting14
- PPTs8
Shilpa Medicare Limited has informed the Exchange regarding a press release dated September 11, 2026, titled "Shilpa Medicare's Novel Complex Injectable OERIS (Ondansetron Extended-Release Injection, 100 mg/mL) receives final approval from Subject Expert Committee (SEC) for grant of marketing authorization.".
Shilpa Medicare Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on September 11, 2026
The National Company Law Tribunal has admitted an insolvency application against FTF Pharma Private Limited, a wholly owned subsidiary of Shilpa Medicare Limited, ordering the commencement of the Corporate Insolvency Resolution Process. The action stems from an operational debt claim of ₹2,18,03,319/-, resulting in the appointment of an interim resolution...
Shilpa Medicare announced its 39th Annual General Meeting (AGM) on September 11, 2026. The Annual Report for FY25-26 is available, providing investors key insights into the company's financial performance.
Shilpa Medicare voluntarily recalled ~27,900 vials of a chemotherapy drug in the US due to discoloration. This Class II recall is not expected to materially impact the company's financial position or operations.